4.8mg Zenrelia for Dogs - Per Tablet
961176
4.8mg Zenrelia for Dogs
Zenrelia 4.8mg is a once-daily, tablet formulated for dogs aged twelve months and older to manage the itch and inflammation linked to allergic and atopic dermatitis. The active ingredient, ilunocitinib, acts as a non-selective Janus kinase (JAK) inhibitor. It works by interrupting key inflammatory signalling pathways that trigger itch sensations and skin irritation. Zenrelia is not a corticosteroid or antihistamine, but instead targets the underlying immune-mediated mechanisms that fuel pruritus and lesion formation.
Since ilunocitinib is rapidly absorbed and has a short half-life, the tablet begins to provide relief swiftly following administration and clears from the dog’s system within about 24 hours if treatment is paused. This pharmacokinetic profile offers dosing flexibility, permitting treatment to be initiated or stopped as needed, for instance, during diagnostic food trials without lingering drug accumulation.
4.8mg Zenrelia is designed for convenience and compliance. It can be administered with or without food and requires no loading dose or tapering phase. The scoring on the tablets in multiple strengths enables precise dosing from as low as approximately 0.6 mg per kilogram up to 0.8 mg per kilogram (0.27–0.36 mg per pound). This makes Zenrelia adaptable for dogs of different sizes and weight classes.
In clinical trials involving several hundred dogs with allergic or atopic dermatitis, Zenrelia demonstrated rapid reduction in itch scores and skin lesion severity, with outcomes comparable to or exceeding those of existing JAK inhibitors. Visual and numerical assessments showed notable improvements in both itching and inflammation within weeks of treatment commencement. The repeat-daily dosing maintained this effect over the longer term, supporting skin health and owner satisfaction.
VETERINARY PRESCRIPTION REQUIRED
Product Features
- Pack Size: - Sold Individually
- Target Animal: - Dog (Canine)
- Related Condition: - allergic and atopic dermatitis in dogs
- Pet Prescription Required?: - Yes
- Active Ingredient: - ilunocitinib
- Product Name: - 4.8mg Zenrelia Tablet for Dogs
More Information
Description
Allergic dermatitis in dogs includes a range of conditions such as food-related allergies, contact dermatitis, flea bite hypersensitivity, and atopic dermatitis which is a hereditary predisposition to develop allergic reactions to environmental substances like pollen, dust mites or moulds. Atopic dermatitis typically presents with chronic itching, redness, skin lesions, and a disrupted skin barrier. Persistent scratching and inflammation can exacerbate these symptoms, leading to secondary skin infections and further discomfort for the dog.
4.8mg Zenrelia works by reducing the inflammatory signals that drive itch and skin damage. By calming these responses, itch behaviour diminishes and the skin has a chance to heal and regain integrity. This helps break the so-called itch-scratch cycle common in atopic dogs and supports long-term management of chronic skin conditions.
As with any immune-modulating medication, safety considerations are essential. Zenrelia carries a warning regarding immune response to vaccines. Dogs receiving Zenrelia should not be administered modified live vaccines, and vaccination should be withheld for at least 28 days before and after treatment to avoid risk of inadequate immune response or vaccine-induced disease. Therefore, ensuring that a dog’s vaccination schedule is up to date prior to starting treatment is crucial.
Common adverse effects reported include mild gastrointestinal signs such as vomiting, diarrhoea, and occasional lethargy. Dogs should be monitored during therapy for signs of infection, changes in blood parameters such as haematocrit or red blood cell counts, and any emerging tumour growths, as rare neoplastic conditions were observed in clinical studies. The safety of Zenrelia has not yet been established in breeding, pregnant or lactating dogs, and its use alongside systemic immunosuppressants such as glucocorticoids or cyclosporine is not evaluated.
For veterinarians and pet owners seeking an effective treatment for canine allergic itch and atopic dermatitis, Zenrelia offers a targeted approach. It combines rapid action, flexible dosing, and convenience while addressing the underlying inflammatory mechanisms.
